PHAT
Phathom Pharmaceuticals, Inc. Common StockstockNASDAQ
phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 6.23 | 2026-11-12 | -18.78% | 0.083 |
| 1M | 7.01 | 2026-10-19 | -27.82% | 2.579 |
| 3M | 9.32 | 2026-08-19 | -45.71% | 2.257 |
| 6M | 11.40 | 2026-05-19 | -55.61% | 0.959 |
| 1Y | 14.79 | 2025-11-19 | -65.79% | 0.966 |
| 2Y | 9.37 | 2024-11-19 | -46.00% | — |
| 5Y | 20.08 | 2021-11-19 | -74.80% | 1.366 |
Phathom Pharmaceuticals, Inc. Common Stock (NASDAQ:PHAT) stock price today is $5.06, and today's volume is 647,365. PHAT is down 4.528% today. The 30 day average volume is 1.69M. PHAT market cap is $411.34M with 81.29M shares outstanding.